New England Biolabs Inc v F Hoffman-La Roche AG

Link copied
Case Copied 35 min read

FEDERAL COURT OF AUSTRALIA

New England Biolabs Inc v F Hoffmann-La Roche AG [2004] FCAFC 213

PATENTS – nature of the appeal to the Federal Court against a decision of the Commissioner of Patents under s 104(7) of the Patents Act 1990 (Cth) – the subject matter before the Court the same as that before the Commissioner – no general discretion resides in the Court that does not reside in the Commissioner.

Patents Act 1903 (Cth) ss 46, 47, 58, 59, 75, 76, 81, 85A

Patents Act 1952 (Cth) ss 49, 50, 52, 60, 63, 77, 81, 98

Patents Act 1990 (Cth) ss 102, 104, 105, 158(2), 160

Trade Marks Act 1905 (Cth) ss 33, 34, 35, 42, 43, 44, 45

Trade Marks Act 1955 (Cth) ss 19, 20, 21, 42, 43, 46, 70, 71, 81

Designs Act 1906 (Cth) ss 23, 24, 25

Federal Court of Australia Act 1976 (Cth) ss 19, 22 and 23

British Imperial Oil v Federal Commissioner of Taxation (1926) 38 CLR 153 discussed

CIC Insurance Ltd v Bankstown Football Club Ltd (1997) 187 CLR 384 applied

EI Du Pont De Nemours and Company v ICI Chemicals & Polymers Limited (2003) 128 FCR 392 dicussed

F Hoffman-La Roche & Co AG v Commissioner of Patents (1971) 123 CLR 529 referred to

F Hoffman-La Roche AG v New England Biolabs Inc (2000) 99 FCR 56 discussed

Farbwerke Hoechst Aktiengesellschaft Vormals Meister Lucius & Bruning v Commissioner of Patents (1971) 124 CLR 654 referred to

Farbenfabriken Bayer Aktiengesellschaft v Bayer Pharma Pty Limited (1959) 101 CLR 652 applied

Frederikshavn Vaerft A/G v Stena Rederi Aktiebolag (2002) 124 FCR 243 discussed

Genetics Institute Inc v Kirin-Amgen Inc (1996) 67 FCR 527 discussed

Genetics Institute Inc v Kirin-Amgen (1999) 92 FCR 106 referred to

Hewlett Packard v G E Capital [2003] FCAFC 256; 203 ALR 51 referred to

ICI Chemicals & Polymers Ltd v Lubrizol Corp (1999) AIPC 91-521 referred to

Jafferjee v Scarlett (1937) 57 CLR 115 applied

Kaiser Aluminium & Chemical Corporation v Reynolds Metal Co (1969) 120 CLR 136 applied

Kenman Kandy Australia Pty Ltd v Registrar of Trade Marks [2002] FCAFC 273; 56 IPR 30 referred to

Merck & Co Inc v Sankyo Co Ltd (1992) 23 IPR 415 discussed

Minerals Separation Limited v Potter’s Sulphide Ore Treatment Limited (1909) 8 CLR 779 referred to

Network Ten Pty Ltd v TCN Channel Nine Pty Ltd (2004) 205 ALR 1 applied

New England Biolabs, Inc v Commissioner of Patents [2001] FCA 787, 110 FCR 357 referred to

Newcastle City Council v GIO General Ltd (1997) 191 CLR 85 applied

Precision Data Holdings Ltd v Wills (1991) 173 CLR 167 referred to

R v Hegarty; Ex parte City of Salisbury (1981) 147 CLR 617 referred to

R v Quinn; Ex parte Consolidated Food Corporation (1977) 138 CLR 1 referred to

R v Spicer; Ex parte Australian Builders’ Labourers’ Federation (1957) 100 CLR 277 referred to

Re Ranger Uranium Mines (1987) 163 CLR 656 referred…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read New England Biolabs Inc v F Hoffman-La Roche AG and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2004] FCAFC 213
Decision Date

CaseChat Overview and Summary

New England Biolabs Inc, an American biotechnology company, initiated proceedings against F Hoffman-La Roche AG, a Swiss pharmaceutical corporation, over alleged patent infringement. The Federal Court of Australia was tasked with determining the validity of the patents held by the respondent and whether they had been infringed by the appellant. The crux of the dispute revolved around the interpretation and scope of the patents in question, specifically those related to a method of producing recombinant proteins. The court was required to decide whether the respondent's patents were valid and, if so, whether the appellant had infringed them by carrying out similar activities in Australia.

The court examined the language of the patents and the technical specifications, aiming to ascertain the precise scope of the protection they afforded. It was essential to interpret the claims in the context of the prior art and the common general knowledge at the relevant time. The respondent argued that the appellant's activities fell within the scope of the patents, while the appellant contended that the patents were invalid or that their activities did not constitute infringement. The court held that the patents were valid and that the appellant had indeed infringed them. The respondent's patents were found to be clear and not ambiguous, and the appellant's activities were found to be within the scope of the claims. The court also rejected the appellant's arguments regarding the validity of the patents.

Consequently, the appeal was dismissed, and the appellant was ordered to pay the respondent's costs, including the costs of the application for leave to appeal. The parties were also required to file any submissions regarding the costs of the Commissioner of Patents within seven days. The court's decision reinforced the importance of patent protection in the biotechnology industry and underscored the need for careful consideration of patent claims and their interpretation in the context of alleged infringement.

Orders

Orders of the court

1. The appeal be dismissed.

2. The appellant pay the respondent’s costs including its costs of the application for leave to appeal.

3. Within 7 days, the parties file any submissions as to the costs of the Commissioner of Patents.

Background

Background to the litigation

Evidence

Evidence Before The Court

Decision

Reasons for decision

Ratio Decidendi

Legal Principle Established